This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Infinity (INFI) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Infinity (INFI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Karyopharm Stock Up Even as FDA Delays Selinexor NDA Verdict
by Zacks Equity Research
Karyopharm's (KPTI) stock rises despite the FDA's decision to delay the verdict on the NDA filing of selinexor, which is developed for treating patients with relapsed-refractory multiple myeloma.
Spectrum Pharma (SPPI) Withdraws Rolontis BLA, Shares Down
by Zacks Equity Research
Spectrum Pharma (SPPI) withdraws the BLA seeking approval for Rolontis, as the FDA requests for additional manufacturing-related data.
Infinity Inks Deal With Roche for Phase II Study of IPI-549
by Zacks Equity Research
Shares of Infinity (INFI) rise after the company inks deal with Roche to initiate a phase II MARIO-3 study on IPI-549. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity.
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Infinity (INFI) delivered earnings and revenue surprises of 17.65% and 192.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Infinity (INFI) Down 48.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bristol-Myers, Infinity to Test Opdivo Combo for Bladder Cancer
by Zacks Equity Research
Bristol-Myers (BMY) signs a contract with Infinity Pharmaceuticals to evaluate the combination of its Pd-1 inhibitor Opdivo and Infinity's IPI-549 for treating advanced urothelial cancer
Infinity (INFI) Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Infinity (INFI) beats earnings estimates in the third quarter of 2018. The company revised its outlook for 2018 and expects net loss for 2018 to be $10-$20 million, down from its previous expectation of $35-$45 million.
Infinity Pharmaceuticals (INFI) Looks Good: Stock Adds 6.5% in Session
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
5 Best Biotech Stocks to Buy In October
by Zacks Equity Research
Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October
Options Traders Expect Huge Moves in Infinity (INFI) Stock
by Zacks Equity Research
Infinity (INFI) needs investors to pay close attention to the stock based on moves in the options market lately.
Infinity (INFI) Up 21.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Infinity Focuses on Developing IPI-549 for Solid Tumors
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) aims at developing its pipeline candidate, IPI-549.
Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Infinity (INFI) posts narrower-than-expected loss in the second quarter of 2018 and provides update on pipeline candidate, IPI 549.
Infinity and Arcus Ink Deal for Two Triple Combo Studies
by Zacks Equity Research
: Infinity Pharmaceuticals, Inc. (INFI) and Arcus Biosciences, Inc. (RCUS) sign a deal to evaluate two triple combination therapies in selected tumor types.
Is the Options Market Predicting a Spike in Infinity (INFI) Stock?
by Zacks Equity Research
Investors in Infinity (INFI) need to pay close attention to the stock based on moves in the options market lately.
Infinity Pharmaceuticals (INFI) Down 6.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Infinity (INFI) Incurs In-Line Loss in Q1, Maintains View
by Zacks Equity Research
Infinity (INFI) reports in-line loss in Q1 and maintains its 2018 guidance.
Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates
by Zacks Equity Research
Conatus (CNAT) reports in-line loss in Q1 while revenues beat estimates. Moreover, the top line improves year over year.
Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y
by Zacks Equity Research
Acorda's (ACOR) earnings and revenues lag estimates in Q1. The company reiterates its 2018 outlook for the key drug Ampyra.
Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y
by Zacks Equity Research
Allergan's (AGN) first-quarter 2018 earnings surpass estimates with revenues also marginally beating the same. Moreover, the company ups its adjusted earnings and sales view for the full year.
Medicines Company's (MDCO) Q1 Loss Widens, Revenues Tank Y/Y
by Zacks Equity Research
The Medicines Company (MDCO) incurs wider-than-expected loss in the first quarter of 2018. The top line also missed estimates and declined year over year.
AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains
by Zacks Equity Research
AbbVie's (ABBV) Q1 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline
by Zacks Equity Research
The FDA approval for Agios' (AGIO) only marketed drug, Idhifa, augurs well for long-term growth. The company is also well on progress track with its lead candidate, ivosidenib, for R/R AML.